Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Horizon Therapeutics plc
< Previous
1
2
3
4
5
6
Next >
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
September 22, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
September 21, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
September 19, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
September 16, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
September 14, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day
September 13, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
September 12, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces $500 Million Share Repurchase Program
September 09, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List
September 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
August 31, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
August 29, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
August 25, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
August 15, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
August 03, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named a Best Company for Multicultural Women
July 25, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
July 21, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
July 11, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
July 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
July 07, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
June 24, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
June 15, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
June 15, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
June 11, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Named a Top Company for Executive Women
June 09, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
June 06, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
June 02, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy
June 01, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
May 31, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
May 31, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
May 24, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Tickers
HZNP
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.